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Background
Cryo is an effective modality for pain palliation and local
control of soft tissue and bone metastases. Cryo induces
necrotic cell death, and combination cryo with anti-
CTLA-4 generates potent systemic anti-tumor immune
responses in preclinical models and small clinical studies.
However, the clinical activity of cryo plus checkpoint
blockade has not been evaluated in MM. In this pilot
study, we report the safety and efficacy of IT cryo and sys-
temic ipilimumab or pembrolizumab in patients with MM.
Methods
A single-institution study of 16 MM patients who received
IT cryo during systemic therapy of checkpoint blockade.
Pts with at least 1 symptomatic lesion amenable for cryo
were included. Cryo was performed under ultrasound or
CT-guidance. Data of symptom control, toxicity assess-
ment and responses were collected prospectively and con-
tinued after 12 weeks of treatment administration.
Exploratory immune correlates from peripheral blood and
tumor samples were obtained when available.
Results
12 out of 16 treated pts are evaluable at this time. Median
age was 60 years (range: 58-82). All pts received cryo
after 1 or 2 doses of either ipilimumab (N=8) or pembro-
lizumab (N=4). 8 patients had BRAF-V600 mutation and
3 had NRAS mutation. 10 pts had stage-IV disease (M1a:
2, M1b: 1, M1c: 7) and 2 had unresectable stage III. 4 pts
were treatment naïve and 8 received 1-5 prior treatments.
Objective response rates (ORR) of cryoablated (local)
lesions were 75% (9/12), ORR of distant lesions were 40%
(4/10) and total ORR (local+distant) were 50% (2 [with
local lesions only] + 4 [distant] = 6/12) (ipilimumab-63%
(5/8), pembrolizumab-25% (1/4)) by RECIST 1.1. Local
disease control rates (DCR) were 83%, distant DCR were
60%, and overall DCR were 75%. With a median follow-
up of 7 months, the progression-free survival rate at
6 months was 57%. At the time of the analysis, the med-
ian progression-free survival and overall survival have not
been reached. Grade 3 immune related (irAE) toxicities
were observed in 2 patients including colitis and hypo-
physitis. There were no other grade ¾ irAEs or toxicities
related to cryo. Immunological analysis is ongoing.
Conclusions
The study results suggest that the combination of cryo
with checkpoint blockades is safe, well-tolerated and
could potentially be an effective strategy to enhance the
anti-tumor activity. These findings, warrant further eva-
luation in a larger prospective trial.
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